YAP1 and neoplasm: In 75.6% of ccRCC patients YAP1 immunoreactivity was absent in the cytoplasm of tumor cells; however, in 13/54 (24.1%) of ccRCC patients tumor cells exhibited weak to moderate cytoplasmic YAP1 immunoreactivity (Figure 1(b)).